Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

NCT00310479

Prostate Cancer

COMPLETED NA

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

NCT00082147

Prostate Cancer

COMPLETED NA

Contrast Enhanced MRI of the Prostate

NCT02245282

Prostatic Neoplasms

COMPLETED

18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

NCT04487847

Prostate Cancer

COMPLETED PHASE1/PHASE2

Magnetic Resonance Imaging and Spectroscopy of the Prostate

NCT00590993

Prostate Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High risk prostate cancer patients

Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.

Magnetic Resonance Spectroscopy Imaging with rectal probe

Intervention Type PROCEDURE

Low risk prostate cancer patients

Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 \[3+4\] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health \& Science University's Advanced Imaging Research Center.

Magnetic Resonance Spectroscopy Imaging with rectal probe

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Spectroscopy Imaging with rectal probe

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Magnetic Resonance Spectroscopy Imaging MRSI Magnetic Resonance Imaging MRI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prostate cancer diagnosis prior to treatment
* Age 21 years or older
* Signed informed subject consent
* Prostatectomy as planned prostate cancer treatment

Exclusion Criteria

* Men who do not choose prostatectomy
* Men who have undergone any neoadjuvant therapy
* Men who have cardiac pacemakers or other implanted electronic devices
* Men who have any surgically implanted metal
* Men who have had any surgical procedure that precludes placement of endorectal probe
* Indication of dementia or memory issues listed on problem list
* Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray
* Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

Minimum Eligible Age

21 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No